The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Functional and survival effect of bevacizumab and irinotecan administered at recurrence in a cohort of patients with GBM.
E. Tabouret
No relevant relationships to disclose
M. Barrie
No relevant relationships to disclose
C. Boucard
No relevant relationships to disclose
M. Matta
No relevant relationships to disclose
D. Autran
No relevant relationships to disclose
A. Loundou
No relevant relationships to disclose
O. L. Chinot
Consultant or Advisory Role - Roche
Research Funding - Roche